New directions in growth hormone treatment in children

Renata Stawerska

doi:10.5114/pedm.2025.158544

eISSN: 2083-8441
ISSN: 2081-237X

Pediatric Endocrinology Diabetes and Metabolism

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Suplementy Rada naukowa Recenzenci Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne Standardy etyczne i procedury

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Otwarty dostęp

Zintegrowane z publons

4/2025
vol. 31

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

Artykuł redakcyjny

Nowe kierunki w leczeniu hormonem wzrostu u dzieci

Renata Stawerska

^{1, 2}

Department of Paediatric and Adult Endocrinology, Medical University of Lodz, Poland
Department of Endocrinology and Metabolic Diseases, Polish Mother’s Memorial Hospital – Research Institute, Lodz, Poland

Pediatr Endocrinol Diabetes Metab 2025; 31 (4): 143-154

DOI: https://doi.org/10.5114/pedm.2025.158544

Data publikacji online: 2026/01/27

Plik artykułu:

- Editorial New directions.pdf [0.69 MB]

Pobierz cytowanie

Metryki PlumX:

1. Ranke MB, Wit JM. Growth hormone – past, present and future. Nat Rev Endocrinol. 2018; 14: 285–300. doi: 10.1038/nrendo.2018.22.

2. Maghnie M, Ranke MB, Geffner ME, et al. Safety and efficacy of pediatric growth hormone therapy: results from the full KIGS cohort. J Clin Endocrinol Metab 2022; 107: 3287–3301. doi: 10.1210/clinem/dgac517.

3. Sävendahl L, Polak M, Backeljauw P, et al. Long-term safety of growth hormone treatment in childhood: two large observational studies (NordiNet IOS and ANSWER). J Clin Endocrinol Metab 2021; 106: 1728–1741. doi: 10.1210/clinem/dgab080.

4. Aydın BK, Aycan Z, Sıklar Z, et al. Adherence to growth hormone therapy: results of a multicenter study. Endocr Pract 2014; 20: 46–51. doi: 10.4158/EP13194.OR.

5. Gomez R, Ahmed SF, Maghnie M, et al. Treatment adherence to injectable treatments in pediatric growth hormone deficiency compared with other chronic pediatric conditions: a systematic review. Front Endocrinol (Lausanne) 2022; 13: 795224. doi: 10.3389/fendo.2022.795224.

6. Rivolo S, Loftus J, Peter B, Fahey M, Kongnakorn T. Cost-effectiveness and cost-utility analysis of once-weekly somatrogon versus daily growth hormone for pediatric GHD in Ireland. J Med Econ 2023; 26: 963–972. doi: 10.1080/13696998.2023.2228167.

7. European Medicines Agency. Skytrofa (lonapegsomatropin): Summary of Product Characteristics. EMA/740430/2021 Rev.5; 2022. Accessed May 17, 2025.

8. European Medicines Agency. Sogroya (somapacitan): Summary of Product Characteristics. EMEA/H/005030 Rev.2; 2021. Accessed May 17, 2025.

9. European Medicines Agency. Ngenla (somatrogon): Summary of Product Characteristics. EMEA/H/C/005633 Rev.4; 2022. Accessed May 17, 2025.

10. Chatelain P, Malievskiy O, Radziuk K, et al. A randomized phase 2 study of long-acting TransCon GH versus daily GH in childhood growth hormone deficiency. J Clin Endocrinol Metab 2017; 102: 1673–1682. doi: 10.1210/jc.2016-3608.

11. Thornton PS, Maniatis AK, Aghajanova E, et al. Weekly lonapegsomatropin in treatment-naïve children with growth hormone deficiency: the phase 3 heiGHt trial. J Clin Endocrinol Metab 2021; 106: 3184–3195. doi: 10.1210/clinem/dgab529.

12. Maniatis AK, Casella SJ, Nadgir UM, et al. Safety and efficacy of lonapegsomatropin in children with growth hormone deficiency: enliGHten trial 2-year results. J Clin Endocrinol Metab 2022; 107: e2680–e2689. doi: 10.1210/clinem/dgac217.

13. Maniatis AK, Thornton PS, Nadgir UM, et al. Sustained height improvements up to 6 years in children with growth hormone deficiency treated with lonapegsomatropin: enliGHten final results. Horm Res Paediatr. 2025; 2025: 1–13. doi: 10.1159/000545064.

14. Sävendahl L, Battelino T, Rasmussen MH, et al. Weekly somapacitan in growth hormone deficiency: 4-year efficacy, safety, and treatment burden (REAL 3). J Clin Endocrinol Metab 2023; 108: 2569–2578. doi: 10.1210/clinem/dgad183.

15. Miller BS, Blair JC, Rasmussen MH, et al. Weekly somapacitan in children with growth hormone deficiency: the randomized phase 3 REAL4 trial. J Clin Endocrinol Metab 2022; 107: 3378–3388. doi: 10.1210/clinem/dgac513.

16. Brod M, Rasmussen MH, Alolga S, et al. Psychometric validation of the GHD-CTB and GHD-PTB instruments. Pharmacoecon Open 2023; 7: 121–138. doi: 10.1007/s41669-022-00373-z.

17. Miller BS, Blair JC, Rasmussen MH, et al. REAL4 2-year results and outcomes after switching from daily GH to somapacitan. J Clin Endocrinol Metab 2023; 108: 3090–3099. doi: 10.1210/clinem/dgad394.

18. Miller BS, Blair JC, Rasmussen MH, et al. Three-year efficacy, safety, and IGF-I outcomes of weekly somapacitan in children with GHD. Eur J Endocrinol 2025; 192: 651–661. doi: 10.1093/ejendo/lvaf096.

19. Zadik Z, Zelinska N, Iotova V, et al. Five-year results from an open-label extension of a phase 2 study of once-weekly somatrogon. J Pediatr Endocrinol Metab 2023; 36: 261–269. doi: 10.1515/jpem-2022-0359.

20. Deal CL, Steelman J, Vlachopapadopoulou E, et al. Weekly somatrogon versus daily somatropin in children with growth hormone deficiency: a phase 3 study. J Clin Endocrinol Metab 2022; 107: e2717–e2728. doi: 10.1210/clinem/dgac220.

21. Deal CL, Steelman J, Vlachopapadopoulou E, et al. Comparing weekly somatrogon with daily somatropin: a plain-language summary. Ther Adv Endocrinol Metab 2024; 15: 20420188241277404. doi: 10.1177/20420188241277404.

22. ClinicalTrials.gov. NCT03831880. Patient perception of treatment burden in weekly versus daily GH injections in children with GHD. Accessed May 17, 2025.

23. Loftus J, Quitmann J, Valluri SR. Health-related quality of life in prepubertal children treated with once-weekly somatrogon versus daily somatropin. Curr Med Res Opin 2024; 40: 175–184. doi: 10.1080/03007995.2023.2290623.

24. Choe J, Cara J, Stawerska R, et al. Results from the open-label extension of a global phase 3 study of once-weekly somatrogon in pediatric patients with growth hormone deficiency. 21st International Congress of Endocrinology 2024, Dubai, 01-03.03.2024. Abstract: 587.

25. Silverman L, Steelman J, Choe J, et al. Up to 5 years of once-weekly somatrogon treatment in pediatric patients with growth hormone deficiency: results from an open-label extension of a global Phase 3 study. 62nd Annual ESPE, Liverpool, 16-18.11.2024. Abstract: 8 P2-351.

26. Albers N, Cadarette S, Feakins B, et al. Long-acting growth hormone for pediatric growth hormone deficiency. J Endocr Soc 2025; 9: bvaf040. doi: 10.1210/jendso/bvaf040.

27. Horikawa R, Tanaka T, Hasegawa Y, et al. Once-weekly somatrogon versus daily somatropin in Japanese children with pediatric GHD. Horm Res Paediatr 2022; 95: 275–285. doi: 10.1159/000524600.

28. Khadilkar V, Radjuk KA, Bolshova E, et al. Twenty-four–month use of once-weekly GH (LB03002) in prepubertal children with GHD. J Clin Endocrinol Metab 2014; 99: 126–132.

29. Maniatis A, Cutfield W, Dattani M, et al. Long-acting growth hormone therapy in pediatric growth hormone deficiency: a consensus statement. J Clin Endocrinol Metab 2024; 110: e1232–e1240. doi: 10.1210/clinem/dgae834.

30. Cohen-Sela E, Oren A, Perl L, et al. Introduction of somatrogon in pediatric GHD: real-world insights from a national survey.

31. Endocr Pract 2025; 2025: S1530-891X(25)01272-8. doi: 10.1016/j.eprac.2025.11.008.

32. Büyükgebiz A, Demir A. Severe lipoatrophy in a toddler treated with long-acting growth hormone. Children (Basel) 2025; 12: 58. doi: 10.3390/children12010058.

33. Akhtar S, Berg B, Medina J, et al. Device preference for somapacitan versus somatrogon in patients and caregivers. Med Devices (Auckl) 2024; 17: 427–439. doi: 10.2147/MDER.S484354.

34. Medina J, Ter-Borch G, Kelepouris N, et al. Usability and preference of somapacitan pen versus lonapegsomatropin autoinjector. Patient Prefer Adherence 2025; 19: 1119–1131. doi: 10.2147/PPA.S505952.

35. Woelfle J, Kreitschmann-Andermahr I, Strasburger CJ, et al. Real-world evaluation of the first 100 patients receiving long-acting GH therapy (INSIGHTS-GHT). Orphanet J Rare Dis 2025; 20: 372. doi: 10.1186/s13023-025-03898-8.

36. Coyne E, Muthuvel G, Gutmark-Little I. Switching from daily somatropin to lonapegsomatropin in pediatric GHD. J Pediatr Endocrinol Metab 2025; 38: 248–253. doi: 10.1515/jpem-2024-0496.

37. Boller E, Raveendran S, Smith A, et al. Budget impact analysis of lonapegsomatropin in pediatric GHD. J Med Econ 2025; 28: 1733–1745. doi: 10.1080/13696998.2025.2561472.

38. Walpurgis K, Thomas A, Rauer A, et al. Detection of somatrogon in doping control urine samples. Sci Rep 2025; 15: 13160. doi: 10.1038/s41598-025-96361-4.

39. Johannsson G, Gordon MB, Rasmussen MH, et al. Once-weekly somapacitan in adults with growth hormone deficiency: a phase 3 trial. J Clin Endocrinol Metab 2020; 105: e1358–e1376. doi: 10.1210/clinem/dgaa049.

40. Lewiński A, Karbownik-Lewińska M, Wieczorek-Szukała K, et al. Contribution of ghrelin to the pathogenesis of growth hormone deficiency. Int J Mol Sci 2021; 22: 9066. doi: 10.3390/ijms22169066.

41. Dauber A, Wikiera B, Stawerska R, et al. OraGrowtH210 trial: oral LUM-201 in moderate pediatric GHD. Horm Res Paediatr 2024; 97 (suppl).

Nowe kierunki w leczeniu hormonem wzrostu u dzieci

Renata Stawerska 1, 2

Renata Stawerska

^{1, 2}